Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
Identifieur interne : 001A34 ( PubMed/Corpus ); précédent : 001A33; suivant : 001A35Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
Auteurs : K. Lindemann ; G. Kristensen ; M R Mirza ; L. Davies ; F. Hilpert ; I. Romero ; A. Ayhan ; A. Burges ; M J Rubio ; F. Raspagliesi ; M. Huizing ; G-J Creemers ; M. Lykka ; C K Lee ; V. Gebski ; E. Pujade-LauraineSource :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2016.
Abstract
Data on CA-125 as a predictor of disease progression (PD) in ovarian cancer come predominantly from patients with platinum-sensitive disease receiving chemotherapy alone. We assessed concordance between CA-125-defined and RECIST-defined PD using data from the Gynecologic Cancer InterGroup (GCIG) randomized phase III AURELIA trial in platinum-resistant ovarian cancer (PROC).
DOI: 10.1093/annonc/mdw238
PubMed: 27407100
Links to Exploration step
pubmed:27407100Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.</title><author><name sortKey="Lindemann, K" sort="Lindemann, K" uniqKey="Lindemann K" first="K" last="Lindemann">K. Lindemann</name><affiliation><nlm:affiliation>NSGO and Department of Gynecological Cancer, The Norwegian Radium Hospital, Oslo University Hospital, Oslo stinalindemann@hotmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Kristensen, G" sort="Kristensen, G" uniqKey="Kristensen G" first="G" last="Kristensen">G. Kristensen</name><affiliation><nlm:affiliation>NSGO and Department of Gynecological Cancer and Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital and Institute for Clinical Medicine, Oslo University, Oslo, Norway.</nlm:affiliation></affiliation></author><author><name sortKey="Mirza, M R" sort="Mirza, M R" uniqKey="Mirza M" first="M R" last="Mirza">M R Mirza</name><affiliation><nlm:affiliation>NSGO and Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Davies, L" sort="Davies, L" uniqKey="Davies L" first="L" last="Davies">L. Davies</name><affiliation><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Hilpert, F" sort="Hilpert, F" uniqKey="Hilpert F" first="F" last="Hilpert">F. Hilpert</name><affiliation><nlm:affiliation>AGO and Oncological Center, Hospital Jerusalem, Hamburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Romero, I" sort="Romero, I" uniqKey="Romero I" first="I" last="Romero">I. Romero</name><affiliation><nlm:affiliation>GEICO and Valencia Institute of Oncology, Valencia, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Ayhan, A" sort="Ayhan, A" uniqKey="Ayhan A" first="A" last="Ayhan">A. Ayhan</name><affiliation><nlm:affiliation>GINECO and Baskent University, Ankara, Turkey.</nlm:affiliation></affiliation></author><author><name sortKey="Burges, A" sort="Burges, A" uniqKey="Burges A" first="A" last="Burges">A. Burges</name><affiliation><nlm:affiliation>AGO and Department of Gynecology and Obstetrics, Hospital of University of Munich, Campus Großhadern, Munich, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Rubio, M J" sort="Rubio, M J" uniqKey="Rubio M" first="M J" last="Rubio">M J Rubio</name><affiliation><nlm:affiliation>GEICO and University Hospital Queen Sofía, Córdoba, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Raspagliesi, F" sort="Raspagliesi, F" uniqKey="Raspagliesi F" first="F" last="Raspagliesi">F. Raspagliesi</name><affiliation><nlm:affiliation>MITO and National Tumour Institute of Milan, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Huizing, M" sort="Huizing, M" uniqKey="Huizing M" first="M" last="Huizing">M. Huizing</name><affiliation><nlm:affiliation>BGOG and Antwerp University Hospital, Edegem, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Creemers, G J" sort="Creemers, G J" uniqKey="Creemers G" first="G-J" last="Creemers">G-J Creemers</name><affiliation><nlm:affiliation>DGOG and Catharina Hospital, Eindhoven, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Lykka, M" sort="Lykka, M" uniqKey="Lykka M" first="M" last="Lykka">M. Lykka</name><affiliation><nlm:affiliation>HECOG and University of Athens, Athens, Greece.</nlm:affiliation></affiliation></author><author><name sortKey="Lee, C K" sort="Lee, C K" uniqKey="Lee C" first="C K" last="Lee">C K Lee</name><affiliation><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Gebski, V" sort="Gebski, V" uniqKey="Gebski V" first="V" last="Gebski">V. Gebski</name><affiliation><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Pujade Lauraine, E" sort="Pujade Lauraine, E" uniqKey="Pujade Lauraine E" first="E" last="Pujade-Lauraine">E. Pujade-Lauraine</name><affiliation><nlm:affiliation>GINECO and Paris Descartes University, AP-HP Central Paris University Hospitals, Paris, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27407100</idno><idno type="pmid">27407100</idno><idno type="doi">10.1093/annonc/mdw238</idno><idno type="wicri:Area/PubMed/Corpus">001A34</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A34</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.</title><author><name sortKey="Lindemann, K" sort="Lindemann, K" uniqKey="Lindemann K" first="K" last="Lindemann">K. Lindemann</name><affiliation><nlm:affiliation>NSGO and Department of Gynecological Cancer, The Norwegian Radium Hospital, Oslo University Hospital, Oslo stinalindemann@hotmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Kristensen, G" sort="Kristensen, G" uniqKey="Kristensen G" first="G" last="Kristensen">G. Kristensen</name><affiliation><nlm:affiliation>NSGO and Department of Gynecological Cancer and Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital and Institute for Clinical Medicine, Oslo University, Oslo, Norway.</nlm:affiliation></affiliation></author><author><name sortKey="Mirza, M R" sort="Mirza, M R" uniqKey="Mirza M" first="M R" last="Mirza">M R Mirza</name><affiliation><nlm:affiliation>NSGO and Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Davies, L" sort="Davies, L" uniqKey="Davies L" first="L" last="Davies">L. Davies</name><affiliation><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Hilpert, F" sort="Hilpert, F" uniqKey="Hilpert F" first="F" last="Hilpert">F. Hilpert</name><affiliation><nlm:affiliation>AGO and Oncological Center, Hospital Jerusalem, Hamburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Romero, I" sort="Romero, I" uniqKey="Romero I" first="I" last="Romero">I. Romero</name><affiliation><nlm:affiliation>GEICO and Valencia Institute of Oncology, Valencia, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Ayhan, A" sort="Ayhan, A" uniqKey="Ayhan A" first="A" last="Ayhan">A. Ayhan</name><affiliation><nlm:affiliation>GINECO and Baskent University, Ankara, Turkey.</nlm:affiliation></affiliation></author><author><name sortKey="Burges, A" sort="Burges, A" uniqKey="Burges A" first="A" last="Burges">A. Burges</name><affiliation><nlm:affiliation>AGO and Department of Gynecology and Obstetrics, Hospital of University of Munich, Campus Großhadern, Munich, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Rubio, M J" sort="Rubio, M J" uniqKey="Rubio M" first="M J" last="Rubio">M J Rubio</name><affiliation><nlm:affiliation>GEICO and University Hospital Queen Sofía, Córdoba, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Raspagliesi, F" sort="Raspagliesi, F" uniqKey="Raspagliesi F" first="F" last="Raspagliesi">F. Raspagliesi</name><affiliation><nlm:affiliation>MITO and National Tumour Institute of Milan, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Huizing, M" sort="Huizing, M" uniqKey="Huizing M" first="M" last="Huizing">M. Huizing</name><affiliation><nlm:affiliation>BGOG and Antwerp University Hospital, Edegem, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Creemers, G J" sort="Creemers, G J" uniqKey="Creemers G" first="G-J" last="Creemers">G-J Creemers</name><affiliation><nlm:affiliation>DGOG and Catharina Hospital, Eindhoven, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Lykka, M" sort="Lykka, M" uniqKey="Lykka M" first="M" last="Lykka">M. Lykka</name><affiliation><nlm:affiliation>HECOG and University of Athens, Athens, Greece.</nlm:affiliation></affiliation></author><author><name sortKey="Lee, C K" sort="Lee, C K" uniqKey="Lee C" first="C K" last="Lee">C K Lee</name><affiliation><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Gebski, V" sort="Gebski, V" uniqKey="Gebski V" first="V" last="Gebski">V. Gebski</name><affiliation><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Pujade Lauraine, E" sort="Pujade Lauraine, E" uniqKey="Pujade Lauraine E" first="E" last="Pujade-Lauraine">E. Pujade-Lauraine</name><affiliation><nlm:affiliation>GINECO and Paris Descartes University, AP-HP Central Paris University Hospitals, Paris, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Data on CA-125 as a predictor of disease progression (PD) in ovarian cancer come predominantly from patients with platinum-sensitive disease receiving chemotherapy alone. We assessed concordance between CA-125-defined and RECIST-defined PD using data from the Gynecologic Cancer InterGroup (GCIG) randomized phase III AURELIA trial in platinum-resistant ovarian cancer (PROC).</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">27407100</PMID><DateCreated><Year>2016</Year><Month>07</Month><Day>26</Day></DateCreated><DateRevised><Year>2016</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1569-8041</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>8</Issue><PubDate><Year>2016</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title><ISOAbbreviation>Ann. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.</ArticleTitle><Pagination><MedlinePgn>1505-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdw238</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Data on CA-125 as a predictor of disease progression (PD) in ovarian cancer come predominantly from patients with platinum-sensitive disease receiving chemotherapy alone. We assessed concordance between CA-125-defined and RECIST-defined PD using data from the Gynecologic Cancer InterGroup (GCIG) randomized phase III AURELIA trial in platinum-resistant ovarian cancer (PROC).</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Patients with PROC were randomized to receive single-agent chemotherapy with or without bevacizumab. PD by CA-125 was defined according to GCIG criteria (except that confirmatory CA-125 measurement was not required). This exploratory analysis included patients with RECIST PD and a CA-125 reading ≤28 days before and ≤21 days after RECIST-defined PD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 218 eligible patients, only 94 (43%, 95% confidence interval 36% to 50%) had concordant RECIST and CA-125 PD status (42% in the chemotherapy-alone arm; 45% in the bevacizumab combination arm, P = 0.6). There was no evidence of CA-125-defined PD in the remaining 124 patients despite PD according to imaging. There were no significant differences in baseline characteristics between patients with PD defined by both RECIST and CA-125 and those with RECIST-only PD. CA-125 was even less sensitive in detecting PD in patients with early (<8 weeks after randomization) compared with later RECIST-defined PD (69% versus 53%, respectively, not meeting CA-125 criteria; P = 0.053). There was no significant difference in survival after PD in patients with concordant PD by RECIST and CA-125 versus those with PD only by RECIST. We validated our findings in an independent study population of PROC.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this platinum-resistant population, PD was typically detected earlier by imaging than by CA-125, irrespective of bevacizumab treatment. Disease status by CA-125 at the time of PD was not prognostic for overall survival. Regular radiologic assessment as well as symptom benefit assessment should be considered during PROC follow-up.</AbstractText><CopyrightInformation>© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lindemann</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>NSGO and Department of Gynecological Cancer, The Norwegian Radium Hospital, Oslo University Hospital, Oslo stinalindemann@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kristensen</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>NSGO and Department of Gynecological Cancer and Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital and Institute for Clinical Medicine, Oslo University, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirza</LastName><ForeName>M R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>NSGO and Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hilpert</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>AGO and Oncological Center, Hospital Jerusalem, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romero</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>GEICO and Valencia Institute of Oncology, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayhan</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>GINECO and Baskent University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burges</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>AGO and Department of Gynecology and Obstetrics, Hospital of University of Munich, Campus Großhadern, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubio</LastName><ForeName>M J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>GEICO and University Hospital Queen Sofía, Córdoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raspagliesi</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>MITO and National Tumour Institute of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huizing</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>BGOG and Antwerp University Hospital, Edegem, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Creemers</LastName><ForeName>G-J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>DGOG and Catharina Hospital, Eindhoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lykka</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>HECOG and University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>C K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gebski</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pujade-Lauraine</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>GINECO and Paris Descartes University, AP-HP Central Paris University Hospitals, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Oncol</MedlineTA><NlmUniqueID>9007735</NlmUniqueID><ISSNLinking>0923-7534</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CA-125</Keyword><Keyword MajorTopicYN="N">RECIST</Keyword><Keyword MajorTopicYN="N">ovarian cancer</Keyword><Keyword MajorTopicYN="N">platinum resistance</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>03</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>05</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27407100</ArticleId><ArticleId IdType="pii">mdw238</ArticleId><ArticleId IdType="doi">10.1093/annonc/mdw238</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A34 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001A34 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27407100
|texte= Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27407100" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |